NRx Pharmaceuticals, Inc. (NRXP)
| Market Cap | 117.24M +90.6% |
| Revenue (ttm) | 3.39M |
| Net Income | -23.48M |
| EPS | -0.78 |
| Shares Out | 43.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,177,678 |
| Open | 2.530 |
| Previous Close | 2.590 |
| Day's Range | 2.480 - 2.772 |
| 52-Week Range | 1.620 - 5.055 |
| Beta | 2.07 |
| Analysts | Strong Buy |
| Price Target | 38.50 (+1,320.66%) |
| Est. Earnings | Nov 16, 2026 |
About NRXP
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NRXP stock is "Strong Buy." The 12-month stock price target is $38.5, which is an increase of 1,320.66% from the latest price.
News
Psychedelic: NRx Pharmaceuticals receives FDA labeling review letter
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a FDA request, a scientific advisor agreement and a board appointment. NRX…
NRx receives FDA review letter for Ketamine product requesting minor changes
NRx Pharmaceuticals (NRXP) announced the receipt of a “Discipline Review Letter” from the FDA requesting “minor” changes to the submitted label for NRx’s Preservative-Free Ketamine product. The letter...
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by F...
NRx Pharmaceuticals awarded initial $11.18M DARPA prime contract
NRx Defense Systems announced the award of an initial $11,177,757.27 contract issued by the Defense Advanced Research Projects Agency, DARPA, a Branch of the United States Department of War. The…
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are ...
NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’
NRx Pharmaceuticals (NRXP) announced that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the company that the amendment…
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announc...
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env i...
NRx Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Key advances include a preservative-free ketamine (KETAFREE) nearing FDA decision, integration of robotic TMS for depression, and phase II success for NRX-101 in reducing suicidality and akathisia. Commercial launch and profitability are targeted for mid-next year.
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announc...
NRx Pharmaceuticals Transcript: Moody Capital Disruptive Growth & Life Science Conference
A newly acquired biotech is advancing monoclonal antibody therapies targeting endogenous retroviruses for ALS and other diseases, with clinical trials planned by 2027 and strong patent protection. Partnerships span NIH and major research institutes, and a $5M crowdfunding raise is underway.
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that...
NRx Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 marked a pivotal period with regulatory progress on ketamine and NRX-101, expansion of HOPE clinics, and the acquisition of GeNeuro assets. Financials improved with a reduced net loss and a strengthened cash position, supporting near-term launches and clinical growth.
NRx Pharmaceuticals Quarterly report: Q2 2026
NRx Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 17, 2026.
NRx Pharmaceuticals Earnings release: Q2 2026
NRx Pharmaceuticals released its Q2 2026 earnings on August 17, 2026, summarizing the period's financial results.
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
Key recent and second quarter highlights include: Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item...
NRx Pharmaceuticals Transcript: Status update
FDA review of the preservative-free ketamine ANDA is nearly complete, with only a minor clarification outstanding and no major deficiencies. Manufacturing and commercial preparations are ramping up, with five million units planned for launch to address the U.S. ketamine shortage and capture significant market share.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host ...
FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA
NRx Pharmaceuticals (NRXP) announced that the FDA has completed first-cycle review of the company’s ANDA for its preservative-free ketamine, with no major deficiencies related to the drug product, ing...
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC, or other drug-related review matters. Remaining item relates to manufacturer certificati...
NRx Pharmaceuticals issues response to Kadima statements
NRx Pharmaceuticals (NRXP) issued the following statement in response to recent public claims made by Kadima Neuropsychiatry Institute. “Kadima issued a public statement on June 24, 2026 making a seri...
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”) today issued the following statement in response to recent public claims made by K...
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient care AI-powered,...
Kadima Neuropsychiatry Institute alleges NRx breached contract
Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, said the have filed a complaint against NRx Pharmaceuticals (NRXP) in San Diego County Superior Court, alleging breach of contract a...
Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
SAN DIEGO--(BUSINESS WIRE)--Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a complaint against NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and two of its subsidiaries in S...